The Analyst Verdict: Editas Medicine In The Eyes Of 4 Experts
The Analyst Verdict: Editas Medicine In The Eyes Of 4 Experts
分析师的判决：4位专家眼中的Editas医学
Across the recent three months, 4 analysts have shared their insights on Editas Medicine (NASDAQ:EDIT), expressing a variety of opinions spanning from bullish to bearish.
在最近三个月中，4位分析师分享了他们对Editas Medicine（纳斯达克股票代码：EDIT）的见解，表达了从看涨到看跌的各种观点。
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
下表简要介绍了他们最近的收视率，展示了过去30天中不断变化的情绪，并将其与前几个月进行了比较。
Analysts have set 12-month price targets for Editas Medicine, revealing an average target of $9.5, a high estimate of $15.00, and a low estimate of $7.00. Highlighting a 32.14% decrease, the current average has fallen from the previous average price target of $14.00.
分析师已经为Editas Medicine设定了12个月的目标股价，显示平均目标股价为9.5美元，最高估计为15.00美元，低估值为7.00美元。当前的平均价格已从之前的平均目标股价14.00美元有所下降，这凸显了32.14％的跌幅。
Investigating Analyst Ratings: An Elaborate Study
调查分析师评级：一项详尽的研究
The standing of Editas Medicine...
通过对分析...
登录免费看全文
登录/注册